Can-Fite BioPharma (NYSE:CANF) Upgraded to Strong-Buy at EF Hutton Acquisition Co. I

Can-Fite BioPharma (NYSE:CANF) was upgraded by research analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research note issued on Wednesday, July 17th, Zacks.com reports.

CANF has been the topic of a number of other reports. StockNews.com initiated coverage on shares of Can-Fite BioPharma in a research report on Thursday, July 11th. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research note on Thursday, May 9th.

Can-Fite BioPharma Stock Performance

Shares of CANF opened at $2.15 on Wednesday. Can-Fite BioPharma has a 52 week low of $1.83 and a 52 week high of $4.69. The stock’s 50-day moving average price is $2.28 and its 200-day moving average price is $2.52.

Hedge Funds Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC grew its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.